News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

TxCell Appoints Marc D. Beer as Chairman of its Supervisory Board

9/25/2008 4:43:41 PM

Valbonne Sophia Antipolis, France, September 10 - TxCell, a leading biotech company, today announced that its Board of Directors has appointed Marc D. Beer as Chairman of the firm's Supervisory Board. TxCell’s strategy is to develop a new class of autologous cellular immunotherapy products that are uniquely designed to regulate a patient's own immune system. TxCell is now entering the first-in-man stage (with a Phase I/IIa clinical trial in Crohn's disease) and is also developing clinical applications in rheumatoid arthritis (RA).

"We are very fortunate to have Marc join as our new Chairman of our Supervisory Board, as he has great experience and a keen understanding of the biotechnology industry in general and cell therapy in particular. We are convinced that Marc has the business acumen and leadership skills to support TxCell’s strategic development," commented Frederic Hammel, TxCell's CEO.

"I am excited and honored to be joining TxCell," stated Marc Beer, the newly appointed Chairman of the Supervisory Board. "I believe in TxCell’s long-term potential benefits for patients with chronic diseases. I look forward to working with the team to forge the road ahead", he added.

About Marc D. Beer

Marc D. Beer joined Cambridge MA-based ViaCell as its Chief Executive Officer in April 2000 and developed the cell screening company through several rounds of private and stock market financing before organizing its acquisition by PerkinElmer Inc. Prior to ViaCell, Marc held a number of senior management positions at Genzyme, most recently serving as Vice President, Global Marketing for Genzyme Therapeutics. Before that, Mr Beer held a variety of management roles at BioStar Inc. and Abbott Laboratories. Marc Beer has more than 20 years' experience in P&L management, sales & marketing and R&D management in therapeutic, surgical and in vitro diagnostics businesses. Mr. Beer received his B.S. in Business Administration from Miami University, Oxford, in 1987

About TxCell

TxCell SA was spun out of INSERM (France's National Institute for Health and Medical Research) in 2001. The company develops novel cell therapies for autoimmune and chronic inflammatory diseases based on the biological properties of regulatory T lymphocytes (Tr1 cells). In 2007, the AFSSAPS (the French Agency for Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn's disease. The first results are expected at the end of this year. The firm is based in the Sophia Antipolis technology park, near Nice in southern France. TxCell has recently moved into new premises that are better suited to its future growth.


TxCell: David Dellamonica Tel: +33(0) 497 218 300

ALIZE RP Caroline Carmagnol Tel : + 33 (0) 664 189 959 Juliette Vandenbroucque Tel : + 33 (0)1 41 22 07 32

Read at

comments powered by Disqus